What happens when a multi-million dollar gene therapy doesn’t deliver long-term durability?

In this second part of our focus on cell and gene therapy, Adam Buckler and Omar Ali dive into one of the biggest payer concerns—buyer’s remorse. As early gene therapies reach the five-year mark, payers are seeing some patients return to their original treatments, raising tough questions about pricing, durability, and reimbursement.

Adam and Omar explore how contracts are evolving to address this, from rebate structures tied to long-term outcomes to proportional refund models based on treatment failure timelines. How are manufacturers adapting? And how can payers ensure value for these high-cost therapies?

Missed last week’s episode? In part one we explored the initial access challenges for these groundbreaking treatments.

Watch Next